

Minimal Residual Disease Market Size, Trends, Analysis, and Outlook By Test, Polymerase Chain Reaction, Fluorescence In Situ Hybridization (FISH), Next Generation Sequencing (NGS)), By Detection Target (Leukemia, Lymphoma, Solid Tumors, Others), By End-User (Hospitals, Laboratory centers, Specialty Clinics), by Country, Segment, and Companies, 2024-2032

<https://marketpublishers.com/r/M1BA22D01CDDEN.html>

Date: April 2024

Pages: 205

Price: US\$ 3,980.00 (Single User License)

ID: M1BA22D01CDDEN

Abstracts

The global Minimal Residual Disease market size is poised to register 12.6% growth from 2024 to 2032, presenting significant growth prospects for companies operating in the industry. The industry study analyzes the global Minimal Residual Disease market across By Test, Polymerase Chain Reaction, Fluorescence In Situ Hybridization (FISH), Next Generation Sequencing (NGS)), By Detection Target (Leukemia, Lymphoma, Solid Tumors, Others), By End-User (Hospitals, Laboratory centers, Specialty Clinics)

The minimal residual disease (MRD) market is witnessing rapid growth driven by the increasing adoption of MRD testing in hematological malignancies, the growing emphasis on personalized treatment strategies, and advancements in molecular diagnostics, flow cytometry, and next-generation sequencing technologies that enable sensitive detection and monitoring of residual cancer cells after therapy initiation, as well as the correlation of MRD status with treatment response, disease recurrence, and long-term outcomes in cancer patients. With advancements in assay sensitivity, standardization efforts, and data interpretation algorithms, there is a rising opportunity for MRD testing providers to offer comprehensive solutions that encompass sample collection, processing, analysis, and reporting while ensuring accuracy, reproducibility,

and clinical utility for oncologists, hematologists, and clinical researchers. Further, the expanding applications of MRD testing in treatment decision-making, risk stratification, and clinical trial enrollment across various cancer types are driving market expansion further.

Minimal Residual Disease Market Drivers, Trends, Opportunities, and Growth Opportunities

This comprehensive study discusses the latest trends and the most pressing challenges for industry players and investors. The Minimal Residual Disease market research analyses the global market trends, key drivers, challenges, and opportunities in the industry. In addition, the latest Future of Minimal Residual Disease survey report provides the market size outlook across types, applications, and other segments across the world and regions. It provides data-driven insights and actionable recommendations for companies in the Minimal Residual Disease industry.

Key market trends defining the global Minimal Residual Disease demand in 2024 and Beyond

The industry continues to remain an attractive hub for opportunities for both domestic and global vendors. As the market evolves, factors such as emerging market dynamics, demand from end-user sectors, a growing patient base, changes in consumption patterns, and widening distribution channels continue to play a major role.

Minimal Residual Disease Market Segmentation- Industry Share, Market Size, and Outlook to 2032

The Minimal Residual Disease industry comprises a wide range of segments and sub-segments. The rising demand for these product types and applications is supporting companies to increase their investment levels across niche segments. Accordingly, leading companies plan to generate a large share of their future revenue growth from expansion into these niche segments. The report presents the market size outlook across segments to support Minimal Residual Disease companies scaling up production in these sub-segments with a focus on expanding into emerging countries.

Key strategies adopted by companies within the Minimal Residual Disease industry

Leading Minimal Residual Disease companies are boosting investments to capitalize on untapped potential and future possibilities across niche market segments and surging

demand conditions in key regions. Further, companies are leveraging advanced technologies to unlock opportunities and achieve operational excellence. The report provides key strategies opted for by the top 10 Minimal Residual Disease companies.

Minimal Residual Disease Market Study- Strategic Analysis Review

The Minimal Residual Disease market research report dives deep into the qualitative factors shaping the market, empowering you to make informed decisions-

Industry Dynamics: Porter's Five Forces analysis to understand bargaining power, competitive rivalry, and threats that impact long-term strategy formulation.

Strategic Insights: Provides valuable perspectives on key players and their approaches based on comprehensive strategy analysis.

Internal Strengths and Weaknesses: Develop targeted strategies to leverage strengths, address weaknesses, and capitalize on market opportunities.

Future Possibilities: Prepare for diverse outcomes with in-depth scenario analysis. Explore potential market disruptions, technology advancements, and economic changes.

Minimal Residual Disease Market Size Outlook- Historic and Forecast Revenue in Three Cases

The Minimal Residual Disease industry report provides a detailed analysis and outlook of revenue generated by companies from 2018 to 2023. Further, with actual data for 2023, the report forecasts the market size outlook from 2024 to 2032 in three case scenarios- low case, reference case, and high case scenarios.

Minimal Residual Disease Country Analysis and Revenue Outlook to 2032

The report analyses 22 countries worldwide including the key driving forces and market size outlook from 2021 to 2032. In addition, region analysis across Asia Pacific, Europe, the Middle East, Africa, North America, and South America is included in the study. For each of the six regions, the market size outlook by segments is forecast for 2032.

North America Minimal Residual Disease Market Size Outlook- Companies plan for focused investments in a changing environment

The US continues to remain the market leader in North America, driven by a large consumer base, the presence of well-established providers, and a strong healthcare infrastructure. Leading companies focus on new product launches in the changing environment. The US healthcare expenditure is expected to grow to \$4.8 trillion in 2024 (around 3.7% growth in 2024), potentially driving demand for various Minimal Residual Disease market segments. Similarly, Strong market demand is encouraging Canadian Minimal Residual Disease companies to invest in niche segments. Further, as Mexico continues to strengthen its relations and invest in technological advancements, the Mexico Minimal Residual Disease market is expected to experience significant expansion, offering lucrative opportunities for both domestic and international stakeholders.

Europe Minimal Residual Disease Market Size Outlook-Companies investing in assessing consumers, categories, competitors, and capabilities

The German industry remains the major market for companies in the European Minimal Residual Disease industry with consumers in Germany, France, the UK, Spain, Italy, and others anticipated to register a steady demand throughout the forecast period, driving the overall market prospects. In addition, the proactive approach of vendors in identifying and leveraging new growth prospects positions the European Minimal Residual Disease market for an upward trajectory, fostering both domestic and international interest. Leading brands operating in the industry are emphasizing effective marketing strategies, innovative product offerings, and a keen understanding of consumer preferences.

Asia Pacific Minimal Residual Disease Market Size Outlook- an attractive hub for opportunities for both local and global companies

The increasing prevalence of indications, robust healthcare expenditure, and increasing investments in healthcare infrastructure drive the demand for Minimal Residual Disease in Asia Pacific. In particular, China, India, and South East Asian Minimal Residual Disease markets present a compelling outlook for 2032, acting as a magnet for both domestic and multinational vendors seeking growth opportunities. Similarly, with a burgeoning population and a rising middle class, India offers a vast consumer market. Japanese and Korean companies are quickly aligning their strategies to navigate changes, explore new markets, and enhance their competitive edge. Our report utilizes

in-depth interviews with industry experts and comprehensive data analysis to provide a comprehensive outlook of 6 major countries in the APAC region.

Latin America Minimal Residual Disease Market Size Outlook- Continued urbanization and rising income levels

Rising income levels contribute to greater purchasing power among consumers, spurring consumption and creating opportunities for market expansion. Continued urbanization and rising income levels are expected to sustainably drive consumption growth in the medium to long term.

Middle East and Africa Minimal Residual Disease Market Size Outlook- continues its upward trajectory across segments

Robust demand from Middle Eastern countries including Saudi Arabia, the UAE, Qatar, Kuwait, and other GCC countries supports the overall Middle East Minimal Residual Disease market potential. Fueled by increasing healthcare expenditure of individuals, growing population, and high prevalence across a few markets drives the demand for Minimal Residual Disease.

Minimal Residual Disease Market Company Profiles

The global Minimal Residual Disease market is characterized by intense competitive conditions with leading companies opting for aggressive marketing to gain market shares. The report presents business descriptions, SWOT analysis, growth strategies, and financial profiles. Leading companies included in the study are Adaptive Biotechnologies Corp, Amgen Inc, AstraZeneca PLC, Bristol-Myers Squibb Company, iRepertoire Inc, Kite Pharma Inc, Natera Inc, Navidea Biopharmaceuticals Inc, Novartis AG, Synimmune GmbH.

Recent Minimal Residual Disease Market Developments

The global Minimal Residual Disease market study presents recent market news and developments including new product launches, mergers, acquisitions, expansions, product approvals, and other updates in the industry.

Minimal Residual Disease Market Report Scope

Parameters: Revenue, Volume Price

Study Period: 2023 (Base Year); 2018- 2023 (Historic Period); 2024- 2032 (Forecast Period)

Currency: USD; (Upon request, can be provided in Euro, JPY, GBP, and other Local Currency)

Qualitative Analysis

Pricing Analysis

Value Chain Analysis

SWOT Profile

Market Dynamics- Trends, Drivers, Challenges

Porter's Five Forces Analysis

Macroeconomic Impact Analysis

Case Scenarios- Low, Base, High

Market Segmentation:

By Test

Polymerase Chain Reaction

Fluorescence In Situ Hybridization (FISH)

Next Generation Sequencing (NGS)

By Detection Target

Leukemia

Lymphoma

Solid Tumors

Others

By End-User

Hospitals

Laboratory centers

Specialty Clinics

Geographical Segmentation:

North America (3 markets)

Europe (6 markets)

Asia Pacific (6 markets)

Latin America (3 markets)

Middle East Africa (5 markets)

Companies

Adaptive Biotechnologies Corp

Amgen Inc

AstraZeneca PLC

Bristol-Myers Squibb Company

iRepertoire Inc

Kite Pharma Inc

Natera Inc

Navidea Biopharmaceuticals Inc

Novartis AG

Synimmune GmbH

Formats Available: Excel, PDF, and PPT

Contents

1. EXECUTIVE SUMMARY

- 1.1 Minimal Residual Disease Market Overview and Key Findings, 2024
- 1.2 Minimal Residual Disease Market Size and Growth Outlook, 2021- 2030
- 1.3 Minimal Residual Disease Market Growth Opportunities to 2030
- 1.4 Key Minimal Residual Disease Market Trends and Challenges
 - 1.4.1 Minimal Residual Disease Market Drivers and Trends
 - 1.4.2 Minimal Residual Disease Market Challenges
- 1.5 Competitive Landscape and Key Players
- 1.6 Competitive Analysis- Growth Strategies Adopted by Leading Minimal Residual Disease Companies

2. MINIMAL RESIDUAL DISEASE MARKET SIZE OUTLOOK TO 2030

- 2.1 Minimal Residual Disease Market Size Outlook, USD Million, 2021- 2030
- 2.2 Minimal Residual Disease Incremental Market Growth Outlook, %, 2021- 2030
- 2.3 Segment Snapshot, 2024

3. MINIMAL RESIDUAL DISEASE MARKET- STRATEGIC ANALYSIS REVIEW

- 3.1 Porter's Five Forces Analysis
 - * Threat of New Entrants
 - * Threat of Substitutes
 - * Intensity of Competitive Rivalry
 - * Bargaining Power of Buyers
 - * Bargaining Power of Suppliers
- 3.2 Value Chain Analysis
- 3.3 SWOT Analysis

4. MINIMAL RESIDUAL DISEASE MARKET SEGMENTATION ANALYSIS AND OUTLOOK

- 4.1 Market Segmentation and Scope
- 4.2 Market Breakdown by Type, Application, and Other Segments, 2021-2030
 - By Test
 - Polymerase Chain Reaction
 - Fluorescence In Situ Hybridization (FISH)

Next Generation Sequencing (NGS)

By Detection Target

Leukemia

Lymphoma

Solid Tumors

Others

By End-User

Hospitals

Laboratory centers

Specialty Clinics

4.3 Growth Prospects and Niche Opportunities, 2023- 2030

4.4 Regional comparison of Market Growth, CAGR, 2023-2030

5. REGION-WISE MARKET OUTLOOK TO 2030

5.1 Key Findings for Asia Pacific Minimal Residual Disease Market, 2025

5.2 Asia Pacific Minimal Residual Disease Market Size Outlook by Type, 2021- 2030

5.3 Asia Pacific Minimal Residual Disease Market Size Outlook by Application, 2021- 2030

5.4 Key Findings for Europe Minimal Residual Disease Market, 2025

5.5 Europe Minimal Residual Disease Market Size Outlook by Type, 2021- 2030

5.6 Europe Minimal Residual Disease Market Size Outlook by Application, 2021- 2030

5.7 Key Findings for North America Minimal Residual Disease Market, 2025

5.8 North America Minimal Residual Disease Market Size Outlook by Type, 2021- 2030

5.9 North America Minimal Residual Disease Market Size Outlook by Application, 2021- 2030

5.10 Key Findings for South America Minimal Residual Disease Market, 2025

5.11 South America Minimal Residual Disease Market Size Outlook by Type, 2021- 2030

5.12 South America Minimal Residual Disease Market Size Outlook by Application, 2021- 2030

5.13 Key Findings for Middle East and Africa Minimal Residual Disease Market, 2025

5.14 Middle East Africa Minimal Residual Disease Market Size Outlook by Type, 2021- 2030

5.15 Middle East Africa Minimal Residual Disease Market Size Outlook by Application, 2021- 2030

6. COUNTRY-WISE MARKET SIZE OUTLOOK TO 2030

- 6.1 US Minimal Residual Disease Market Size Outlook and Revenue Growth Forecasts
- 6.2 US Minimal Residual Disease Industry Drivers and Opportunities
- 6.3 Canada Market Size Outlook and Revenue Growth Forecasts
- 6.4 Canada Minimal Residual Disease Industry Drivers and Opportunities
- 6.6 Mexico Market Size Outlook and Revenue Growth Forecasts
- 6.6 Mexico Minimal Residual Disease Industry Drivers and Opportunities
- 6.7 Germany Market Size Outlook and Revenue Growth Forecasts
- 6.8 Germany Minimal Residual Disease Industry Drivers and Opportunities
- 6.9 France Market Size Outlook and Revenue Growth Forecasts
- 6.10 France Minimal Residual Disease Industry Drivers and Opportunities
- 6.11 UK Market Size Outlook and Revenue Growth Forecasts
- 6.12 UK Minimal Residual Disease Industry Drivers and Opportunities
- 6.13 Spain Market Size Outlook and Revenue Growth Forecasts
- 6.14 Spain Minimal Residual Disease Industry Drivers and Opportunities
- 6.16 Italy Market Size Outlook and Revenue Growth Forecasts
- 6.16 Italy Minimal Residual Disease Industry Drivers and Opportunities
- 6.17 Rest of Europe Market Size Outlook and Revenue Growth Forecasts
- 6.18 Rest of Europe Minimal Residual Disease Industry Drivers and Opportunities
- 6.19 China Market Size Outlook and Revenue Growth Forecasts
- 6.20 China Minimal Residual Disease Industry Drivers and Opportunities
- 6.21 India Market Size Outlook and Revenue Growth Forecasts
- 6.22 India Minimal Residual Disease Industry Drivers and Opportunities
- 6.23 Japan Market Size Outlook and Revenue Growth Forecasts
- 6.24 Japan Minimal Residual Disease Industry Drivers and Opportunities
- 6.26 South Korea Market Size Outlook and Revenue Growth Forecasts
- 6.26 South Korea Minimal Residual Disease Industry Drivers and Opportunities
- 6.27 Australia Market Size Outlook and Revenue Growth Forecasts
- 6.28 Australia Minimal Residual Disease Industry Drivers and Opportunities
- 6.29 South East Asia Market Size Outlook and Revenue Growth Forecasts
- 6.30 South East Asia Minimal Residual Disease Industry Drivers and Opportunities
- 6.31 Rest of Asia Pacific Market Size Outlook and Revenue Growth Forecasts
- 6.32 Rest of Asia Pacific Minimal Residual Disease Industry Drivers and Opportunities
- 6.33 Brazil Market Size Outlook and Revenue Growth Forecasts
- 6.34 Brazil Minimal Residual Disease Industry Drivers and Opportunities
- 6.36 Argentina Market Size Outlook and Revenue Growth Forecasts
- 6.36 Argentina Minimal Residual Disease Industry Drivers and Opportunities
- 6.37 Rest of South America Market Size Outlook and Revenue Growth Forecasts
- 6.38 Rest of South America Minimal Residual Disease Industry Drivers and Opportunities

- 6.39 Middle East Market Size Outlook and Revenue Growth Forecasts
- 6.40 Middle East Minimal Residual Disease Industry Drivers and Opportunities
- 6.41 Africa Market Size Outlook and Revenue Growth Forecasts
- 6.42 Africa Minimal Residual Disease Industry Drivers and Opportunities

7. MINIMAL RESIDUAL DISEASE MARKET OUTLOOK ACROSS SCENARIOS

- 7.1 Low Growth Case
- 7.2 Reference Growth Case
- 7.3 High Growth Case

8. MINIMAL RESIDUAL DISEASE COMPANY PROFILES

- 8.1 Profiles of Leading Minimal Residual Disease Companies in the Market
 - 8.2 Business Descriptions, SWOT Analysis, and Growth Strategies
 - 8.3 Financial Performance and Key Metrics
- Adaptive Biotechnologies Corp
Amgen Inc
AstraZeneca PLC
Bristol-Myers Squibb Company
iRepertoire Inc
Kite Pharma Inc
Natera Inc
Navidea Biopharmaceuticals Inc
Novartis AG
Synimmune GmbH.

9. APPENDIX

- 9.1 Scope of the Report
- 9.2 Research Methodology and Data Sources
- 9.3 Glossary of Terms
- 9.4 Market Definitions
- 9.5 Contact Information

I would like to order

Product name: Minimal Residual Disease Market Size, Trends, Analysis, and Outlook By Test, Polymerase Chain Reaction, Fluorescence In Situ Hybridization (FISH), Next Generation Sequencing (NGS)), By Detection Target (Leukemia, Lymphoma, Solid Tumors, Others), By End-User (Hospitals, Laboratory centers, Specialty Clinics), by Country, Segment, and Companies, 2024-2032

Product link: <https://marketpublishers.com/r/M1BA22D01CDDEN.html>

Price: US\$ 3,980.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/M1BA22D01CDDEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below
and fax the completed form to +44 20 7900 3970